LGVN Stock Posts

LGVN Longeveron - Class A3.53+0.60+20.5%

Premarket:2.52-1.01 (-28.6%)

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Globe NewswireWed, 17-Apr 8:00 AM

LGVN Longeveron9.98+1.05+11.8%

Premarket:10.72+0.74 (+7.4%)

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial

Globe NewswireWed, 13-Apr 8:00 AM

LGVN Longeveron6.72-0.24-3.5%

Premarket:8.80+2.08 (+31.0%)

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Globe NewswireThu, 31-Mar 8:00 AM

LGVN Longeveron11.60-0.49-4.1%

Premarket:14.50+2.90 (+25.0%)

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer's Disease

Globe NewswireWed, 5-Jan 8:00 AM

LGVN Longeveron20.12+2.12+11.8%

After Hours:19.75-0.37 (-1.8%)

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

Globe NewswireFri, 3-Dec 4:30 PM

LGVN Longeveron2.92-0.20-6.6%

Premarket:4.07+1.15 (+39.4%)

U.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

Globe NewswireThu, 18-Nov 8:00 AM